Innogenetics receives unanimous verdict against Abbott

By Elaine Rigoli

Tampa, Fla., Sept. 5 - Innogenetics NV's hepatitis C virus genotyping patent was found enforceable, valid and infringed by Abbott Laboratories in a patent infringement action in the U.S. District Court for The Western District of Wisconsin.

A jury unanimously upheld the validity of Innogenetics' patent, U.S. Patent No. 5,846,704, which claims a method of genotyping the hepatitis C virus.

The dispute began in September 2005 when Gent, Belgium-based biopharmaceutical company Innogenetics brought suit against Abbott Park, Ill.-based Abbott Laboratories alleging that Abbott was infringing its patent.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.